Enhancing Nanoparticle Accumulation and Retention in Desmoplastic Tumors via Vascular Disruption for Internal Radiation Therapy
暂无分享,去创建一个
[1] J. Friedberg,et al. Consolidative Radioimmunotherapy After Chemoimmunotherapy in Patients With Histologic Transformation of Indolent Non-Hodgkin Lymphoma. , 2016, Clinical lymphoma, myeloma & leukemia.
[2] Leaf Huang,et al. Current and Future Theranostic Applications of the Lipid-Calcium-Phosphate Nanoparticle Platform , 2016, Theranostics.
[3] W. Lau,et al. Current role of selective internal radiation with yttrium-90 in liver tumors. , 2016, Future oncology.
[4] Leaf Huang,et al. A radio-theranostic nanoparticle with high specific drug loading for cancer therapy and imaging. , 2015, Journal of controlled release : official journal of the Controlled Release Society.
[5] William Y. Kim,et al. Nanoparticle modulation of the tumor microenvironment enhances therapeutic efficacy of cisplatin. , 2015, Journal of controlled release : official journal of the Controlled Release Society.
[6] Xuesi Chen,et al. Coadministration of Vascular Disrupting Agents and Nanomedicines to Eradicate Tumors from Peripheral and Central Regions. , 2015, Small.
[7] A. Haug,et al. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma , 2015, Liver international : official journal of the International Association for the Study of the Liver.
[8] William Y. Kim,et al. Nanoparticles with Precise Ratiometric Co‐Loading and Co‐Delivery of Gemcitabine Monophosphate and Cisplatin for Treatment of Bladder Cancer , 2014, Advanced functional materials.
[9] Yuhua Wang,et al. Unmodified drug used as a material to construct nanoparticles: delivery of cisplatin for enhanced anti-cancer therapy. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[10] Fan Wang,et al. Anti-tumor Effect of Integrin Targeted 177Lu-3PRGD2 and Combined Therapy with Endostar , 2014, Theranostics.
[11] Yuhua Wang,et al. Lipid-coated Cisplatin nanoparticles induce neighboring effect and exhibit enhanced anticancer efficacy. , 2013, ACS nano.
[12] R. Swann,et al. Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy , 2013, Clinical Cancer Research.
[13] Cyrus Chargari,et al. Combination of vascular disrupting agents and ionizing radiation. , 2013, Critical reviews in oncology/hematology.
[14] Paul A Dayton,et al. Validation of dynamic contrast-enhanced ultrasound in rodent kidneys as an absolute quantitative method for measuring blood perfusion. , 2011, Ultrasound in medicine & biology.
[15] R. Jain,et al. Delivering nanomedicine to solid tumors , 2010, Nature Reviews Clinical Oncology.
[16] Paul A Dayton,et al. Quantitative Volumetric Perfusion Mapping of the Microvasculature Using Contrast Ultrasound , 2010, Investigative radiology.
[17] E. Voest,et al. Vascular disrupting agents (VDAs) in anticancer therapy. , 2010, Current clinical pharmacology.
[18] R. Wendt. Beta-ray dose kernels for Ho-166 and Lu-177 , 2010 .
[19] D. Chaplin,et al. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P) , 2009, Expert opinion on investigational drugs.
[20] Stavroula Sofou. Radionuclide carriers for targeting of cancer , 2008, International journal of nanomedicine.
[21] Vicky Goh,et al. Tumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human non-small-cell lung cancer. , 2007, International journal of radiation oncology, biology, physics.
[22] P. LoRusso,et al. Differentiation and definition of vascular-targeted therapies. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[23] Pradeep Tyagi,et al. Anisamide‐targeted stealth liposomes: A potent carrier for targeting doxorubicin to human prostate cancer cells , 2004, International journal of cancer.
[24] C. Kanthou,et al. The biology of the combretastatins as tumour vascular targeting agents , 2002, International journal of experimental pathology.
[25] G. Griffiths,et al. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[26] A. Li,et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. , 1998, International journal of radiation oncology, biology, physics.
[27] G. Tozer,et al. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. , 1997, Cancer research.
[28] M. G. Honig,et al. Dil and DiO: versatile fluorescent dyes for neuronal labelling and pathway tracing , 1989, Trends in Neurosciences.
[29] F. Kiessling,et al. Theranostics: Methods and Protocols , 2019, Methods in Molecular Biology.
[30] F. Lee,et al. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. , 2001, Anticancer research.